Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
Facteur d'impact: 2.9 Facteur d'impact sur 5 ans: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Imprimer: 0743-4863
ISSN En ligne: 2162-660X

Volumes:
Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v18.i2.10
32 pages

Liposomal Formulations of Cyclosporin A: A Biophysical Approach to Pharmacokinetics and Pharmacodynamics

A. Fahr
Department of Pharmaceutical Technology and Biopharmacy, University of Marburg, Ketzerbach 63, 35032 Marburg, Germany
J. Seelig
Department of Biophysical Chemistry, Biocenter of the University of Basel, Klin-gelbergstrabe 70, CH-4056 Basel, Switzerland

RÉSUMÉ

There are about 20 publications about liposomal formulations of Cyclosporin A (CyA) in the pharmaceutical and preclinical literature. Liposomal formulations were developed in order to reduce the nephrotoxicity of CyA and to increase pharmacological effects. However, conflicting results have been published as to the therapeutic properties of these formulations. This is also true for the change in pharmacokinetics and organ distribution of the liposomally encapsulated CyA as compared to conventionally formulated CyA. Using biophysical methods, it could be shown that CyA is not tightly entrapped in liposomal membranes, despite its high lipophilicity. CyA shows retardation only at high lipid concentrations in blood, following a massive injection of liposomes.This effect may diminish nephrotoxicity, as could be demonstrated by in vitro studies using a model tubule system. The results of these studies can be used to predict the formulation behavior in vivo and to optimize liposomal formulations. When applied in an early phase of the drug formulation process, these types of biophysical experiments can also help minimize animal experiments. However, these basic interaction studies cannot cover all physiological, pharmacological, and toxic effects in animals and humans.


Articles with similar content:

Delivery of Biotherapeutics by Inhalation Aerosol
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.12, 1995, issue 2-3
Ralph W. Niven
Drug Delivery to the Nasal Cavity: In Vitro and In Vivo Assessment
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.21, 2004, issue 1
Richard N. Dalby, Gary R. Pitcairn, Stephen P. Newman
Supplementation with a Soluble Beta-Glucan Exported from Shiitake Medicinal Mushroom, Lentinus edodes (Berk.) Singer Mycelium: a Crossover, Placebo-Controlled Study in Healthy Elderly
International Journal of Medicinal Mushrooms, Vol.13, 2011, issue 4
Jowita Sleboda, Minna Nurminiemi, Elling Ulvestad, Ola Gudmundsen, Cecilie Moe, Jean-Michel Gaullier, Erik Snorre Ofjord, Tor Albrektsen
Cardioprotective Effects of ATP-Sensitive Potassium Channels Activation in Experiments in Vivo: Influence on Biochemical Parameters of Blood Following Ischemia-Reperfusion of Myocardium
International Journal of Physiology and Pathophysiology, Vol.1, 2010, issue 4
Oleksander P. Neshcheret, Angela N. Shysh, Roman A. Rovenets, Ruslan B. Strutynskyi, Anatoliy V. Kotsuruba, Oleksiy O. Moibenko
Chlamydia pneumoniae Infection and Inflammatory Diseases
Forum on Immunopathological Diseases and Therapeutics, Vol.7, 2016, issue 3-4
Timothy R. Crother, Rebecca A. Porritt